CN101743005B - 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法 - Google Patents

用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法 Download PDF

Info

Publication number
CN101743005B
CN101743005B CN2008800231969A CN200880023196A CN101743005B CN 101743005 B CN101743005 B CN 101743005B CN 2008800231969 A CN2008800231969 A CN 2008800231969A CN 200880023196 A CN200880023196 A CN 200880023196A CN 101743005 B CN101743005 B CN 101743005B
Authority
CN
China
Prior art keywords
compound
fluoro
imidazo
pyridin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800231969A
Other languages
English (en)
Chinese (zh)
Other versions
CN101743005A (zh
Inventor
A·阿布努布
M·彻迪德
T·A·恩格勒
V·瓦苏德文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101743005(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101743005A publication Critical patent/CN101743005A/zh
Application granted granted Critical
Publication of CN101743005B publication Critical patent/CN101743005B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2008800231969A 2007-07-02 2008-06-20 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法 Expired - Fee Related CN101743005B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
US60/947,512 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012101150238A Division CN102772416A (zh) 2007-07-02 2008-06-20 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物

Publications (2)

Publication Number Publication Date
CN101743005A CN101743005A (zh) 2010-06-16
CN101743005B true CN101743005B (zh) 2013-06-12

Family

ID=39737054

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800231969A Expired - Fee Related CN101743005B (zh) 2007-07-02 2008-06-20 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法
CN2012101150238A Pending CN102772416A (zh) 2007-07-02 2008-06-20 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012101150238A Pending CN102772416A (zh) 2007-07-02 2008-06-20 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物

Country Status (22)

Country Link
US (2) US8318713B2 (enExample)
EP (1) EP2173348B1 (enExample)
JP (2) JP5551589B2 (enExample)
KR (1) KR101230085B1 (enExample)
CN (2) CN101743005B (enExample)
AR (1) AR067112A1 (enExample)
AU (1) AU2008270732B2 (enExample)
BR (1) BRPI0813789A2 (enExample)
CA (1) CA2691587C (enExample)
CL (2) CL2008001848A1 (enExample)
EA (2) EA023697B1 (enExample)
ES (1) ES2561202T3 (enExample)
IL (2) IL202237A (enExample)
MA (1) MA31677B1 (enExample)
MX (1) MX2009013449A (enExample)
MY (1) MY154472A (enExample)
NZ (1) NZ581355A (enExample)
PE (1) PE20090838A1 (enExample)
TW (1) TWI428132B (enExample)
UA (1) UA97400C2 (enExample)
WO (1) WO2009006043A2 (enExample)
ZA (1) ZA200908725B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
SG175207A1 (en) 2009-04-14 2011-11-28 Lilly Co Eli Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
EP2747761A1 (en) * 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
EP3562827A1 (en) * 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CA3222225A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639165A (zh) * 2002-03-05 2005-07-13 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
MY133311A (en) 2002-09-19 2007-11-30 Schering Corp Novel imidazopyridines as cyclin dependent kinase inhibitors
US20110293746A1 (en) 2004-07-09 2011-12-01 Agency For Science, Technology And Research Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders
EP1877569A4 (en) * 2005-05-04 2009-07-15 Univ South Florida PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639165A (zh) * 2002-03-05 2005-07-13 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer

Also Published As

Publication number Publication date
EA201201155A1 (ru) 2014-11-28
MY154472A (en) 2015-06-30
ES2561202T3 (es) 2016-02-25
JP2010532364A (ja) 2010-10-07
CA2691587C (en) 2013-09-24
CL2008001848A1 (es) 2009-05-29
AR067112A1 (es) 2009-09-30
IL218443A0 (en) 2012-04-30
KR20100017984A (ko) 2010-02-16
TW200911272A (en) 2009-03-16
CN102772416A (zh) 2012-11-14
HK1141236A1 (zh) 2010-11-05
JP5551589B2 (ja) 2014-07-16
ZA200908725B (en) 2011-02-23
EA018447B1 (ru) 2013-08-30
MA31677B1 (fr) 2010-09-01
NZ581355A (en) 2012-04-27
CN101743005A (zh) 2010-06-16
CA2691587A1 (en) 2009-01-08
US20100166884A1 (en) 2010-07-01
EA023697B1 (ru) 2016-07-29
US8318713B2 (en) 2012-11-27
EP2173348B1 (en) 2015-12-09
IL202237A0 (en) 2010-06-16
US8648063B2 (en) 2014-02-11
CL2011003046A1 (es) 2012-08-24
JP2014114297A (ja) 2014-06-26
PE20090838A1 (es) 2009-07-02
KR101230085B1 (ko) 2013-02-05
US20130039996A1 (en) 2013-02-14
MX2009013449A (es) 2010-01-15
TWI428132B (zh) 2014-03-01
IL202237A (en) 2014-05-28
EP2173348A2 (en) 2010-04-14
BRPI0813789A2 (pt) 2014-12-30
AU2008270732B2 (en) 2013-01-31
UA97400C2 (uk) 2012-02-10
WO2009006043A3 (en) 2009-04-16
WO2009006043A2 (en) 2009-01-08
AU2008270732A1 (en) 2009-01-08
EA201070085A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
CN101743005B (zh) 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法
ES2705342T3 (es) Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
CN102395372B (zh) 用于治疗造血组织肿瘤和白血病的苯并二氮*衍生物
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
CN104083365A (zh) 癌症的治疗
JP2010532364A5 (enExample)
JP2021505548A (ja) 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用
JP2021519262A (ja) 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
CN102753176A (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
JP7183371B2 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
JP2024516825A (ja) トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン
CN105611934A (zh) 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂
CN116672345A (zh) Parp抑制剂和细胞毒性剂的联合产品及其用途
HK1141236B (en) Potentiation of cancer chemotherapy
CN119770678B (zh) 一种葡萄柚细胞外囊泡负载三功能四价铂化合物的纳米药物及其制备方法和应用
Yue et al. Synthesis and biological evaluation of quinoline derivatives inducing cell apoptosis mediated by PI3K/AKT/mTOR pathway
IL288591B1 (en) Tak-441 for use in cancer treatment in combination with other cancer therapies
Wiedmann et al. Bendamustine-A new approach to the treatment of advanced hepatocellular carcinoma?
HK40038916B (zh) 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒
CN101006080A (zh) 抗癌用cc－1065类似物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130612

Termination date: 20170620

CF01 Termination of patent right due to non-payment of annual fee